Vir Biotechnology, Inc. (VIR) NASDAQ

8.74

-0.29(-3.21%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Marianne De Backer	President, CEO & Director	2.03M	1969
Lawrence Corey	Co-Founder & Scientific Advisor	177,661	1947
Louis J. Picker	Co-Founder & Scientific Advisor	177,661	N/A
Vanina De Verneuil	Executive Vice President, General Counsel & Corporate Secretary	844,344	1979
Jason O'Byrne	Executive Vice President & Chief Financial Officer	984,468	1969
Mark D. Eisner	Executive Vice President & Chief Medical Officer	1.4M	1966
Kiki Patel	Head of Investor Relations	0	N/A
Jennifer Eileen Towne	Executive Vice President & Chief Scientific Officer	0	N/A
Carolyn Wang	Senior Vice President of Corporate Communications	0	N/A
Brent Sabatini	Senior Vice President, Principal Accounting Officer & Chief Accounting Officer	0	1974
Maninder Hora	Executive Vice President & Chief Technical Operations Officer	0	1954

Name

Title

Pay

Year Born

Marianne De Backer

President, CEO & Director

2.03M

1969

Lawrence Corey

Co-Founder & Scientific Advisor

177,661

1947

Louis J. Picker

Co-Founder & Scientific Advisor

177,661

N/A

Vanina De Verneuil

Executive Vice President, General Counsel & Corporate Secretary

844,344

1979

Jason O'Byrne

Executive Vice President & Chief Financial Officer

984,468

1969

Mark D. Eisner

Executive Vice President & Chief Medical Officer

1.4M

1966

Kiki Patel

Head of Investor Relations

N/A

Jennifer Eileen Towne

Executive Vice President & Chief Scientific Officer

N/A

Carolyn Wang

Senior Vice President of Corporate Communications

N/A

Brent Sabatini

Senior Vice President, Principal Accounting Officer & Chief Accounting Officer

1974

Maninder Hora

Executive Vice President & Chief Technical Operations Officer

1954

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.